Safety and immunogenicity of live varicella virus vaccine in children with human immunodeficiency virus type 1.
Live varicella virus vaccine was administered to 10 stable human immunodeficiency virus type 1 (HIV-1)-infected children. Subjects were monitored for adverse reactions, HIV-1 plasma levels, CD4 T cell counts and immune responses. The vaccine was well-tolerated. Varicella-zoster virus-specific lymphocyte proliferative responses were detected in all subjects by 4 weeks and in 9 of 10 subjects 1 year after vaccination.
Division of General Pediatrics, Childrens Hospital Los Angeles, University of Southern California, USA.
Saro H
SH
Armenian
Jin Young
JY
Han
Theresa M
TM
Dunaway
Joseph A
JA
Church
D002644:Chickenpox / Q000517:prevention & control*; D019433:Chickenpox Vaccine / Q000008:administration & dosage / Q000009:adverse effects* / Q000276:immunology*; D002648:Child; D002675:Child, Preschool; D015658:HIV Infections / Q000276:immunology* / Q000821:virology; D015497:HIV-1; D014645:Herpesvirus 3, Human / Q000276:immunology; D006801:Humans; D007223:Infant; D014611:Vaccination
D019433:Chickenpox Vaccine